American College of Clinical Pharmacy
      Search      Cart


NIH Panel Issues April 29 Update to COVID-19 Treatment Guidelines

April 29, 2022

NIH Panel Issues April 29 Update to COVID-19 Treatment Guidelines

The COVID-19 Treatment Guidelines Panel (the Panel) has released a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

The Guideline updates include:

  • The Definition for the C strength of recommendation rating (optional) has been changed from “optional” to “weak” to better reflect the strength of the Panel’s recommendations.
  • New dosing guidance has been added to Prevention of SARS-CoV-2 Infection for people who received an initial dose of tixagevimab 150 mg plus cilgavimab 150 mg for pre-exposure prophylaxis (PrEP).
  • The Ivermectin section was updated with the results from 2 recent, large randomized controlled trials. The Panel now recommends against the use of ivermectin for the treatment of COVID-19, except in clinical trials.
  • Anti-SARS-CoV-2 Monoclonal Antibodies recommendations now include information on the role of bebtelovimab in the treatment of nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progression. Also, sotrovimab is no longer recommended as a treatment option for patients with COVID-19 because it has substantially reduced in vitro activity against the Omicron BA.2 subvariant.
  • The COVID-19 Convalescent Plasma section has been revised to reflect changes to the COVID-19 convalescent plasma (CCP) EUA and the Panel’s latest recommendations.

For complete details on these updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.